Straight, research-focused comparisons of the leading incretin peptides — how they differ in receptor targets, published trial data and regulatory status. Body Pharm pens are research products, not approved medicines.
Retatrutide vs tirzepatide compared: receptor targets, trial weight-loss data, regulatory status and dosing. A clear, research-focused breakdown of the two incretin peptides.
Read comparison →Tirzepatide vs semaglutide: dual vs single receptor action, STEP and SURMOUNT trial data, approvals and dosing. A clear research-focused comparison of the two incretin peptides.
Read comparison →Retatrutide vs semaglutide: triple vs single receptor action, trial weight-loss data, approval status and dosing. A research-focused comparison of the two peptides.
Read comparison →We use cookies for analytics and marketing to improve your experience. You can accept or reject non-essential cookies. Privacy Policy